Quick-Med Technologies Granted Third U.S. Patent for NIMBUS(R) Technology

Issuance Significantly Expands Intellectual Property


GAINESVILLE, Fla., May 7, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a leader in developing innovative antimicrobial technologies for the healthcare and consumer markets, today announced that it has been granted U.S. Patent No. 7,709,694 from the United States Patent and Trademark Office (USPTO). The patent for company's proprietary NIMBUS® polymeric antimicrobial technology is applicable to a variety of base materials including woven and nonwoven fabrics. 

"This patent issuance significantly enhances the current protection for our proprietary NIMBUS technology, further validating its innovative nature," said J. Ladd Greeno, Quick-Med's CEO. "Further, the patent underscores our leadership in developing the first non-leaching antimicrobial available in a wound dressing. While other antimicrobial dressings rely on the release of chemicals into the wound bed that can impede the wound healing process, a non-leaching antimicrobial dressing represents a significant improvement."

The broad range of materials covered under the provisions of the patent include those that are composed of natural fibers, such as cotton and wool, as well as synthetics such as polyurethane, polyester, nylon and polypropylene. The applications included in the allowed claims are for a full spectrum of products such as medical devices including wound and burn dressings and blood transfer and storage products, surgical drapes and gowns, bedding, industrial and military protective wear and consumer apparel plus hygienic products such as wipes, diapers and feminine care.

About NIMBUS

NIMBUS technology employs a safe, eco-friendly active agent that remains in full concentration on any of several substrates. It controls a broad range of both Gram-positive and Gram-negative bacteria. The NIMBUS antimicrobial is not depleted in use, maintains effectiveness even in the presence of large amounts of blood or body fluids, and by design, poses no risk of bacteria developing resistance.

NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is available in BIOGUARD™ barrier dressings from Derma Sciences and Medline, under a private label agreement with Derma Sciences. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the healthcare and consumer markets. Quick-Med is developing NIMBUS applications in several other advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.    

© 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® is a registered trademark of Quick-Med Technologies, Inc. BIOGUARD™ is a trademark of Derma Sciences, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.



            

Mot-clé


Coordonnées